Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

NYXH - Nyxoah SA So'nggi Yangiliklar | Finranks

Home

/

NYXH

N

Nyxoah SA (NYXH)

NGM – Real vaqt narxi. Valyuta: USD

1.57

-0.02 (-1.26%)

Bozor ochiq: Aug 12, 2026, 1:13 PM EDT

1.59

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah Q2 Earnings Call Highlights

Nyxoah Q2 Earnings Call Highlights

Nyxoah NASDAQ: NYXH reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequentially to €2.5 million.

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2026. Financial and Operating Highlights Financials U.S. net revenue for the second quarter of 2026 was €5.2 million, 22% sequential growth over U.S. net revenue for the first quarter of 2026 Global net revenue for the second quarter of 2026 was €7.7 million, 21% sequential growth over global net revenue for the first quarter of 2026 Global net revenue for the first half of 2026 was €14.0 million, as compared to €2.4 million for the first half of 2025 Secured $110 million in aggregate financing during the second quarter of 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2026. Financial and Operating Highlights Financials U.S. net revenue for the second quarter of 2026 was €5.2 million, 22% sequential growth over U.S. net revenue for the first quarter of 2026 Global net revenue for the second quarter of 2026 was €7.7 million, 21% sequential growth over global net revenue for the first quarter of 2026 Global net revenue for the first half of 2026 was €14.0 million, as compared to €2.4 million for the first half of 2025 Secured $110 million in aggregate financing during the second quarter of 2026.